上海
*仅供医学专业人士阅读参考
精准筛选，方显“靶化”价值：EGFR突变晚期NSCLC一线治疗的临床实践与思考。
*以下内容仅供医疗卫生专业人士浏览。
参考文献
[1]DUAN J, et al. Aumolertinib with carboplatin–pemetrexed versus aumolertinib for nonsmall cell lung cancer with EGFR and concomitant tumor suppressor genes (ACROSS2): An open‐label, multicenter, randomized phase 3 study[J/OL]. CA: A Cancer Journal for Clinicians, 2026, 76(2): e70071.
[2]SKOULIDIS F, et al. Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy[J/OL]. Nature Reviews Cancer, 2019, 19(9): 495-509.
审核编码：HS-P-A505A-2609-01925 有效期至：2027-09-12
*此文仅用于向医疗卫生专业人士提供科学信息，不代表平台立场。
特别声明：以上内容(如有图片或视频亦包括在内)为自媒体平台“网易号”用户上传并发布，本平台仅提供信息存储服务。
Notice: The content above (including the pictures and videos if any) is uploaded and posted by a user of NetEase Hao, which is a social media platform and only provides information storage services.
